Frias JP, Nauck MA, Van J, Kutner ME, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in
patients with type 2 diabetes: a randomised, placebo-controlled and active
comparator-controlled phase 2 trial. Lancet 2018 Oct 3. pii: S0140-6736(18)32260.
PMID: 30293770
![]() |
![]() |
![]() |
Free Medical Abstracts
Privacy Policy
Sponsors
Share
About
© Amedeo 1997-2016